Pharma: Page 33
-
David Dee Delgado via Getty Images
Pfizer gets first positive result for an RSV vaccine in pregnant women
The shot kept newborns from getting severe respiratory infections in a Phase 3 trial, paving the way for the drugmaker to seek approval before its top rivals.
By Jonathan Gardner • Nov. 1, 2022 -
Courtesy of Eli Lilly
Lilly sales of new diabetes drug accelerate on rising patient demand
Company executives highlighted the “viral nature” of demand for Mounjaro, which was approved in May for diabetes and has also shown a strong weight-loss benefit in clinical testing.
By Ned Pagliarulo • Nov. 1, 2022 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Mario Tama via Getty Images
J&J to buy heart device maker Abiomed for $16.6B
The deal is the biggest by J&J since its $30 billion buyout of Actelion in 2017, and comes as the company works to split its consumer health business from its pharma and medtech units.
By Elise Reuter • Nov. 1, 2022 -
Permission granted by Bristol-Myers Squibb
With positive trial results, Bristol Myers looks to widen use of blood disease drug
Reblozyl, one of the drugmaker’s key assets, outperformed an older anemia drug in early-stage myelodysplastic syndrome, which could double the number of potentially eligible patients.
By Jonathan Gardner • Oct. 31, 2022 -
Khanchit+khirisutchaluai/Shutterstock.com
Sponsored by GoodRxInflation Reduction Act: What are the healthcare implications?
The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.
Oct. 31, 2022 -
EMA looks to follow the FDA in limiting use of certain immune-regulating drugs
The new recommendations could further curtail use of so-called JAK inhibitors, though restrictions imposed in Europe are less severe than in the U.S.
By Christopher Newman • Oct. 28, 2022 -
Courtesy of Sanofi
Sanofi reveals setback for cancer drug acquired in Synthorx buyout
Disappointing study results have led the French pharma company to take a $1.6 billion impairment charge and plan new early-stage trials for a drug executives once called a potential “foundation” for newer immunotherapy combinations.
By Ben Fidler • Oct. 28, 2022 -
Warren Little via Getty Images
GSK shelves filing plans for arthritis drug after trial results
GSK said the drug, formerly a top prospect licensed from German biotech Morphosys, showed “limited efficacy” in a Phase 3 study of patients with rheumatoid arthritis.
By Delilah Alvarado • Oct. 27, 2022 -
Merck reveals chairman succession as earnings beat forecasts
CEO Robert Davis will take over leadership of the board from Ken Frazier on Dec. 1, one and a half years after being named the company’s chief executive.
By Ned Pagliarulo • Oct. 27, 2022 -
Mario Tama via Getty Images
J&J wins approval of new kind of multiple myeloma drug
The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease. It joins a group of medicines on market that target a protein called BCMA.
By Kristin Jensen • Oct. 26, 2022 -
Novartis sales of Zolgensma gene therapy slow as market shifts
Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.
By Ned Pagliarulo • Oct. 25, 2022 -
Christopher Furlong via Getty Images
AstraZeneca’s persistence pays off with Imjudo approval
After failing multiple studies, the company’s immunotherapy tremelimumab is cleared to treat liver cancer as part of a regimen that could challenge a similar drug combination from Bristol Myers Squibb.
By Jonathan Gardner • Oct. 24, 2022 -
Novartis rival to AstraZeneca rare disease drugs succeeds in study
The pharma said iptacopan, one of its top pipeline prospects, outperformed Alexion’s Soliris and Ultomiris in certain patients with a disease called PNH.
By Ned Pagliarulo • Oct. 24, 2022 -
Finbarr Webster via Getty Images
Pfizer planning steep price hike for COVID-19 vaccine
The company is considering charging as much as between $110 and $130 per dose — roughly four times the vaccine’s current price — once sales transition to the private market.
By Ned Pagliarulo • Oct. 21, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers takes aim at Merck with Opdivo results in early melanoma
New data could support approval in a setting for which Merck’s Keytruda is already available — the latest salvo in the longrunning battle between the two immunotherapy rivals.
By Kristin Jensen • Oct. 20, 2022 -
Mario Tama via Getty Images
J&J, flush with cash, says high valuations remain a dealmaking hurdle
“We don’t have to do anything out of desperation,” said CFO Joseph Wolk on J&J’s second quarter earnings call. J&J holds $34 billion in cash and other liquid assets.
By Christopher Newman • Oct. 18, 2022 -
Mateusz/Shutterstock.com
Sponsored by Emergent BiosolutionsThe demand for nanoparticles in drug formulation is rising
Collaborating with an experienced partner, such as a Contract Development & Manufacturing Organization (CDMO), could prove to be invaluable in developing nano-based systems.
By Kate Silver • Oct. 17, 2022 -
Brian Tucker / BioPharma Dive/BioPharma Dive
5 questions facing drugmakers as third quarter earnings begin
The newly enacted drug pricing law, along with Eisai and Biogen’s Alzheimer’s study success, will bring questions for many of the industry’s top companies.
By Jacob Bell , Jonathan Gardner , Ned Pagliarulo • Oct. 17, 2022 -
Dan Kitwood via Getty Images
Pfizer, BioNTech say updated COVID booster raised omicron antibody levels in trial
The findings, which were disclosed in a press release without specific data, are the first immune response results in humans for the reformulated shot targeting the BA.4 and BA.5 substrains.
By Delilah Alvarado • Oct. 13, 2022 -
National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
GSK sets high bar with trial results for RSV vaccine
With data expected for several other vaccines for the respiratory disease, GSK reported positive clinical trial results showing efficacy above 80%.
By Jonathan Gardner • Oct. 13, 2022 -
Maddie Meyer via Getty Images
Merck pays $250M to license Moderna cancer vaccine
The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release.
By Kristin Jensen • Oct. 12, 2022 -
yodiyim via Getty Images
Merck cardiovascular drug succeeds in study, validating $11B buyout bet
Late-stage study results showed sotatercept, which Merck acquired via its Acceleron deal, benefited patients with PAH. The drug could help Merck fill an expected gap in revenue when patents on Keytruda expire.
By Jonathan Gardner • Oct. 10, 2022 -
Sponsored by GoodRx
Worried about provider consolidation? Learn about GoodRx engagement solutions
GoodRx has developed strong relationships with both patients and providers over the past decade and is helping pharmaceutical manufacturers address the changes resulting from this trend.
Oct. 10, 2022 -
Courtesy of Eli Lilly
Lilly looks to speed FDA review of new diabetes drug in obesity
A new fast track designation allows Lilly to begin the process of seeking approval of tirzepatide for obesity, though the drug will need to succeed in a second trial to get to market.
By Jonathan Gardner • Oct. 6, 2022 -
Jacob Bell/BioPharma Dive
Merck expands Singapore hub to support Keytruda, Gardasil
The company opened a packaging facility for its two top-selling products and began work on a plant that will produce next-generation inhalers.
By Christopher Newman • Oct. 6, 2022
Previous
